Predicting CD4 T-cell reconstitution following pediatric haematopoietic stem cell transplantation

Rollo L Hoare, Paul Veys, Nigel Klein, Robin Callard & Joseph F Standing

1. Centre for Mathematics and Physics in the Life Sciences and Experimental Biology, University College London, London, UK

2. Great Ormond Street Institute of Child Health, University College London, London, UK

3. Great Ormond Street Hospital for Children NHS Trust, London, UK

Corresponding Author: Joseph F Standing

Address: Infection, Immunity and Inflammation, UCL Great Ormond Street Institute of Child Health, 30 Guilford Street, London WC1N 1EH, UK.

Email: j.standing@ucl.ac.uk

Phone: +44(0)207 9052370

Number of figures: 5

Number of tables: 2

Keywords: NONMEM, pediatrics, transplantation, pharmacodynamics

Running head: CD4 reconstitution model in children post-transplant

This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process which may lead to differences between this version and the Version of Record. Please cite this article as an 'Accepted Article', doi: 10.1002/cpt.621

This article is protected by copyright. All rights reserved.
1 Abstract

Haematopoietic stem cell transplantation is an increasingly common treatment for children with a range of haematological disorders. Conditioning with cytotoxic chemotherapy and total body irradiation leaves patients severely immunocompromised. T-cell reconstitution can take several years due to delayed restoration of thymic output. Understanding T-cell reconstitution in children is complicated by normal immune system maturation, heterogeneous diagnoses, and sparse uneven sampling due to the long time spans involved. We describe here a mechanistic mathematical model for CD4 T-cell immune reconstitution following pediatric transplantation. Including relevant biology and using mixed-effects modelling allowed the factors affecting reconstitution to be identified. Bayesian predictions for the long-term reconstitution trajectories of individual children were then obtained using early post-transplant data. The model was developed using data from 288 children; its predictive ability validated on data from a further 75 children, with long-term reconstitution predicted accurately in 81% of patients.
2 Introduction

Haematopoietic stem cell transplantation (HSCT) is used to treat a range of malignant and non-malignant disorders, including leukaemias, immunodeficiencies, metabolic disorders, haemoglobinopathies and marrow failure. Prior to HSCT patients usually receive conditioning to eradicate disease and reduce or ablate the host immune system to prevent rejection. This comes in the form of radiotherapy, cytotoxic chemotherapy, and anti-lymphocyte antibodies. Conditioning leaves patients severely immunocompromised and liable to both opportunistic infections and re-emergence of latent infections such as adenovirus, cytomegalovirus and Epstein-Barr virus. Infection constitutes a major cause of mortality from HSCT.

Following HSCT, the reconstitution of some haematopoietic cells (e.g. neutrophils) is fast, taking a matter weeks. However, the reconstitution of others including CD4 T lymphocytes is slow, taking months to years, requiring extended patient follow-up post HSCT. CD4 T cells are crucial to immune function, and a recent study in children receiving antithymocyte globulin showed successful CD4 T cell reconstitution was associated with improved survival.

Identifying patient characteristics associated with slow reconstitution, and predicting individual reconstitution trajectories will prove useful in both designing new studies of conditioning protocols and in clinical management post-HSCT. Predicting T cell reconstitution in children is complex however because the time scales of reconstitution are similar to that of immune system development. Furthermore, children receive HSCT for a variety of reasons and at different ages, so collating large datasets will result in heterogeneity in patient characteristics.

Studies to date have tended to use small homogeneous groups of patients and assessed reconstitution by either taking the concentration of lymphocyte subsets at certain pre-
determined time points after HSCT \cite{3,4,5,6}, or measuring the time taken to reach pre-determined concentrations \cite{1,7,8,9}. These approaches do not study the entire population receiving HSCT, and through summarising available data, only evaluate the rate or extent of the reconstitution, not both.

A mathematical model of all available data can give both the rate and extent of reconstitution by deriving a trajectory for CD4 concentration with time. Mixed-effects modelling makes it possible to fit mathematical models to the sparse, uneven and heterogeneous data available, while removing bias by accounting for correlations in subjects’ data through parameter-level inter-individual variability \cite{10}. Such models can be used for the design and analysis of clinical trials. Recently it has been shown that using a mechanistic model fitted to all data points rather than comparative statistical test at a single time point can increase the power to detect drug effects by up to 10-fold \cite{11}. Future clinical trials on new agents for conditioning using mechanistically modelled CD4 response as an outcome could therefore be conducted with substantially fewer patients than a traditional study design.

In this paper we present a novel mechanistic mathematical model for CD4 T-cell reconstitution following pediatric HSCT. To delineate age-related effects from other important covariates, we used *a priori* scaling of production and loss terms in the model. This was based on previous models taking T cell receptor excision circle (TREC) and Ki67 expression to infer changes in thymic output, proliferation and loss with age \cite{12,13}. We firstly use the model to identify the factors significantly associated with reconstitution, and secondly to make individualised predictions for long-term reconstitution using these covariates and CD4 T cell counts from the first six months post-HSCT.
3 Results

Mechanistic model building

The raw data (CD4 T cell concentrations in blood) from children following HSCT are given in Fig 1. A one-compartment turnover model was used whereby new cells enter the compartment from the thymus, and cells may then proliferate or die (Fig. 2). Functions were included to account for the underlying biology of the system. The homeostatic mechanisms, and in particular competition for resources such as cytokines and self-peptide MHC, were represented by dependence of both proliferation and loss on cell concentrations 14;15;16;17. Age dependence of proliferation and loss were included in the model to account for the dynamics of the system known to slow with age 12;13;18. Thymic output was also modelled as age dependent as the thymus involutes with age and T cell production decreases. Finally the model accounts for the delay to production of T cells by the thymus following HSCT shown by analysis of previous data for TREC's and recent thymic emigrants 3;19;20. The mathematical functions used are described in the Methods section.

Parameter estimates for the model-building dataset are given in Table 1. The typical CD4 T cell concentration returned to 90% of the expected value for age, and then followed the expected trajectory of a healthy child. It took on average 22 months for a typical child of median age at the time of HSCT to reconstitute to this CD4 concentration for age, varying from 17 months for a 1 year old to 33 months for a 10 year old. The mean delay for thymic output to recover to 50% production was found to be 5 months. Thymic output recovery was fast, with the time taken to recover from 10% to 90% being 3.5 months. After the thymic output recovered, the thymic output for a typical child of median age was found to peak at
200 cells/day, in the region expected for a healthy child of that age. The covariates tested are listed in Table 2.

The type of conditioning affects the reconstitution

Parameter estimates for T cell concentration at the time of HSCT were lower with two of the conditioning drugs, alemtuzumab and antithymocyte globulin (ATG). For patients having neither of these drugs ($n=151$), the model parameter estimate for the mean initial CD4 concentration was 178 cells/μL, while for those who had alemtuzumab ($n=158$) the estimated mean was decreased by 83% to 30.6 cells/μL ($P<0.001$), and for those who had ATG ($n=10$) by 95% to 8.4 cells/μL ($P<0.001$). This resulted in a delayed reconstitution (Fig. 3).

Although the estimated initial mean number of cells in patients who received no conditioning ($n=41$) was unaffected, reconstitution was found to result in a lower long-term concentration, below that expected of a healthy child (Fig. 3).

Leukaemia patients have higher CD4 concentrations

Leukaemia patients ($n=95$) were estimated to have a higher long-term CD4 concentration following HSCT than those with other conditions ($P<0.001$) (Fig. 3). Both lymphoblastic leukaemia patients ($n=45$) and myeloid leukaemia patients ($n=50$) were found to have significantly higher long-term CD4 concentrations, although there was no significant difference between them ($P=0.23$).

Having acute GvHD is associated with a higher initial CD4 concentration

The estimated mean initial CD4 concentration for patients who had acute GvHD ($n=102$) was 33% higher than those for whom there was no reported GvHD ($P<0.001$) (Fig. 3). Model diagnostics from the full covariate model are given in Fig. 4.
Bayesian predictions of reconstitution trajectories

A separate validation dataset that had not been used for model-building was used to assess the predictive ability of the model. To illustrate the model’s potential usefulness, individual parameter estimates were generated using CD4 concentrations measured in the 6 months post HSCT and the individual’s relevant covariates. These individual parameter estimates were used to produce a predicted reconstitution trajectory which was compared with actual post 6-month measurements not used in the model for up to three years post-HSCT.

In 81% (n=61) of the patients, the model gave a good prediction, with over 75% of the observed data within the model confidence intervals, and the correct trend of CD4 reconstitution identified. Examples of good predictions in nine patients are highlighted in Figure 5), whilst predictions for all patients are in Supplementary Materials (Supplementary Fig. 3). The highlighted patients were chosen to have ages from across the spectrum of the data and a spread of the covariates used in the model. Patients 102 and 120 were chosen to demonstrate that two individuals with similar age and the same covariates can have substantially different reconstitution pathways predicted by the model, guided by early CD4 concentrations. Also of note is patient 130 who from early measurements could be thought at risk of poor recovery, but the model showed normal expected long-term recovery, as confirmed by later observations.
4 Discussion

A novel mechanistic model of CD4 T cell reconstitution following HSCT in children has been developed. HSCTs are performed in heterogeneous groups of patients each requiring a stratified approach to conditioning and follow-up treatment. Prolonged CD4 T cell count following HSCT leaves patients at risk of mortality and morbidity due to opportunistic infection, so understanding factors associated with reconstitution is vital. Our model now has the potential to be used in a clinical trial setting\textsuperscript{11} or in multivariable analysis of cohort studies\textsuperscript{1} to tease out studied treatment effects from other important covariates. Furthermore, the model has the ability to predict reconstitution on an individual basis. A major part of the clinical management of patients post-transplant is in immunosuppressant dosing to limit GvHD whilst preventing graft failure, carried out alongside managing infective and other complications with other (potentially interacting) drug and cell therapies. Monitoring CD4 counts forms an important guide to this process, and Bayesian predictions from our model reported alongside CD4 counts will aid clinicians in making treatment decisions in the post-transplant period.

Predictions were made from the model for individual patients in another dataset, using only their covariates and data up to 6 months post HSCT. Predictions were then validated for up to three years after the HSCT, with accurate predictions in 81\% of patients tested. Using the individual patient’s variance-covariance matrix we were able to provide confidence intervals on the predicted trajectory, the size of which being a reflection of the amount of information available on that patient. Predictions were formed using data from the first 6 months. Earlier predictions could be made, but the accuracy of the resulting predictions decreased as the confidence intervals of the predictions increased. Similarly, as new measurements of CD4 concentrations were taken, the predictions could be updated; with each
additional data point, the parameter estimates improve and the confidence intervals decrease. With the validating dataset in this study, using data from the first 3 months rather than 6 increased the size of the confidence intervals by a mean of 10%, while using data from the first 12 months decreased confidence intervals by 12%.

Previous studies have reported a median CD4 count in the range of 100–150 cells/μL at three months post HSCT \(^3;4;5;22\) and 500–1000 cells/μL at one year post HSCT \(^3;5;9\), which agrees well with the our model output for a typical child aged 37 months of 105 cells/μL at three months and 984 cells/μL at one year. Similarly, the time taken to reach 500 cells/μL was around 10.1 months (range 1.1–55.3 months) in a previous study \(^7\); our model predicts 7.5 months for a median-aged child varying from 5.3 months for a one year old to 14.3 months for a 10 year old child. Hence the model-based approach we present builds on previous work by simultaneously analysing the rate and extent of reconstitution. Furthermore, the model appears to give realistic estimates of mean CD4 T cell lifespan of 130, 300 and 550 days for a one, 10 and 18 year old respectively. These agree with recent analyses of labelling studies with estimates between 222 and 611 (range 167 to 1245) days. \(^21;23\).

In searching for significant covariates associated with recovery, we firstly sought to delineate the effect of age, which is a potential confounder since normal CD4 count changes radically with age, and children of different ages will receive HSCTs for different reasons. Rather than correct each data point for an age-expected value as has previously been done \(^24\), we chose to scale the model parameters to age-expected values using biological prior information on thymic output and markers for competition and loss.

Thymic output for age was predicted from a previous study \(^13\). The absolute value of the prediction was uncertain due to a constant for Ki67 expression duration, and more recent work has indicated that thymic output could be as little as 10% of that predicted \(^21\). As such, we used a scaling factor, \(\alpha\), thereby retaining the shape of the expected thymic output with age.
whilst allowing its magnitude to be informed by the data. Our estimate for of 23% of that previously predicted\textsuperscript{13} agrees with these later analyses\textsuperscript{21}. In addition, parameters describing thymic recovery post-HSCT were added, the model predicting 90% production for age taking around 7 months, matching well the experimental evidence of recovery between 5 and 10 months from both TREC analysis\textsuperscript{19;20} and measures of recent thymic emigrants using CD31 expression\textsuperscript{3}.

The covariates listed in Table 2 were tested. Alemtuzumab and ATG are given as pre-transplant conditioning to deplete circulating lymphocytes and have long terminal half-lives (15–21 days for alemtuzumab\textsuperscript{25} and 29.8 days for ATG\textsuperscript{26}). The finding that these drugs were associated with reduced initial CD4 counts was therefore unsurprising. Alemtuzumab and ATG decreased the initial number of cells by 85% and 93% respectively, which is in line with other studies, where alemtuzumab and ATG were associated with later and slower reconstitution in both children and adults\textsuperscript{22;27;28}. A previous study also found that alemtuzumab caused a significantly longer delay to reconstitution than ATG\textsuperscript{29}, which was not observed in the analysis described here, perhaps because our data included very few patients who received ATG.

Those patients who had no pre-transplant conditioning had a reduced mean long-term CD4 concentration, which differs from studies showing reduced conditioning was associated with increased CD4 concentrations\textsuperscript{22;27;28;30}. One possible explanation is that pre-transplant conditioning creates T-cell space allowing donor T-cells to expand more efficiently. Similarly, the finding of increased long-term CD4 concentration for leukaemia patients could be due to these patients receiving full myeloablative conditioning, leaving more space for donor T cell expansion.

Our model also predicted that a raised initial CD4 concentration was associated with incidence of acute GvHD. This agrees with previous studies that found T-cell depleted grafts
to be associated with decreased incidence of acute GvHD \cite{31,32,33,34}. The association was significant on top of the changes in initial mean CD4 concentration caused by alemtuzumab, received by 53% of patients with acute GvHD.

In the covariate analysis, cord blood transplantation (CBT) was not found to be a significant covariate, in agreement with Fernandes et al \cite{35}. In the observed data, patients who have had a cord blood transplant (n=48) as opposed to peripheral blood or bone marrow transplants had a faster reconstitution in the months after the transplant. In the covariate analysis, however, these differences were explained by a combination of the effects of age and pre-transplant conditioning. CBT patients were younger, with 60% of CBT patients under 2 years old (n=29) at the time of HSCT in comparison to 37% of the rest of the model-building dataset and with a median age at HSCT of 1.5 years in comparison to 3.6 years. They were also less likely to have had alemtuzumab or ATG, with 83% (n=40) having neither, in comparison to 41% of the rest of the transplants. This agrees with other studies which have found that age \cite{7} and the omission of ATG \cite{36} can explain the differences observed in the reconstitution of patients following CBT.

In conclusion, a mechanistic model was developed that predicted on an individual basis the long-term immune reconstitution of CD4 T cells following HSCT. The model brought together for the first time many aspects of the immune system following an HSCT including, homeostatic mechanisms, changes to thymic output, loss and proliferation with age, and impaired thymic production of T cells in the months following HSCT. By using this biological prior knowledge in the model, parameter estimates were able to delineate expected age effects from disease and treatment-specific covariates, in addition to separating CD4 production from loss. These predictions allowed for a more informed assessment of the potential long-term position of the patient, and could thus be used to inform clinicians as to the necessity of a change in regimen for that individual patient.

This article is protected by copyright. All rights reserved.
To our knowledge, this was the first time a mechanistic model has been used to predict long-term reconstitution following HSCT in children. As we enter an era of electronic hospital records, there is the potential to use these data directly to provide predicted reconstitution trajectories automatically for children following HSCT, creating a useful tool to inform on the clinical management of these patients.
5 Methods

Data

The dataset used for model building and covariate analysis was collected during routine clinical practice between 2005 and 2011 by the Blood and Marrow Transplant Unit at Great Ormond Street Hospital for Children NHS Trust. The validation dataset was collected in the same manner between 2010 and 2014. The study was approved by the Great Ormond Street Hospital Institutional Review Board and the parents of the patients have provided written informed consent for their data to be used in the database according to the Declaration of Helsinki. The data comprised CD4 T cell concentrations taken at regular intervals for up to seven years after HSCT.

In the modelling dataset, there were 288 patients who had 319 transplants between them. There were 2928 CD4 concentrations in total with a median of 8 (range 1–43) samples taken post transplant. In this dataset, 24% died within the 1–6 year follow-up period; of which, 36% died from infection, 35% from disease relapse and 15% from acute GvHD. In the validation dataset there were 75 patients. A breakdown of the demographics of both datasets is given in Table 2.

Model building

The rate of change in \(X(t)\) (the CD4 T cell concentration with time \(t\) after the HSCT) is,

\[
\frac{d}{dt} X = \lambda - dX + pX
\]

(1)

where \(\lambda\) zero-order thymic output of T cells; \(d\) first-order cell loss rate; and \(p\) first-order proliferation rate. Biological prior knowledge was then incorporated into the model:

*Homeostatic mechanisms and age affect proliferation and loss*
T cell populations are maintained through proliferation and loss. To survive and proliferate, CD4 T cells require interactions with resources, such as cytokines and self-peptide MHC class II complexes. Homeostasis is then maintained through competition for these resources with proliferation and loss concentration-dependent. To model this, we simplify a previous model for the competition effects in T cell homeostasis. The resulting exponential dependence on concentration represents the simplest non-negative functions, whilst adding the fewest parameters to the model. Furthermore the rate of turnover of T cells decreases with age; we use the decrease in Ki67 with age as a marker for proliferation to inform the timescales for these changes, giving,

\[
p = p_0 y(\tau)e^{-c_p \left(1 - \frac{X(\tau)}{N(\tau)}\right)},
\]

\[
d = d_0 y(\tau)e^{-c_d \left(\frac{X(\tau)}{N(\tau)} - 1\right)},
\]

(2)

where \(N(\tau) = 924 + 2354e^{-0.001012\tau}\) is the expected total CD4 concentration in cells/μL for a healthy child of age \(\tau\) days, and \(y(\tau) = 0.02e^{-0.00027\tau}\) is the proportion of CD4 cells expressing Ki67 with age.

Thymic output changes with age

The thymus reaches full size at 1 year, after which thymic output decreases rapidly as thymic epithelial space involutes by 70% over the next 20 years. This change in production was characterised mathematically using TREC dynamics and removing dilution from proliferation, leaving the following function describing the thymic output as a function of age \(\tau\),

\[
\lambda_{age}(\tau) = \frac{y(\tau)N_n(\tau)\tau}{0.02\eta(\tau - y)},
\]

(3)
where $N_n(\tau) = 496.5 + 2074e^{(-0.000869\tau)}$ is the expected naïve CD4 concentration in cells/μL for a healthy child of age $\tau$ days, $\eta=0.52$ days is the duration of Ki67 expression, and $c=0.25$ and $\gamma=0.08$ give the average TREC content of naïve T cells as they leave the thymus and of the naïve T cell pool respectively.

**Thymic output is altered by the HSCT**

Evidence suggests that after HSCT, thymic output of T cells takes between 6 and 10 months to recover. We used a sigmoidal function to model this,

$$
\Delta_{HSCT}(t) = \frac{1 - \frac{t}{\lambda_h}}{1 + \exp\left(\frac{-2t}{\lambda_r}\right)}
$$

where $\lambda_h$ gives the time after HSCT that thymic output increases, and $\lambda_r$ gives the rate of this increase. A sigmoidal function of this form was used because it was found during model development that models where thymic output could be zero immediately post-transplant fitted the data much better. The rate parameter for a standard logistic function was therefore increased in order to make the curves much steeper so that thymic output immediately post HSCT would be zero or close to zero. This made model fitting unstable and gave unrealistic estimates for the recovery rate of thymic output post HSCT, based on evidence from TREC analysis. Similarly, this function fitted the data better than a Hill function. Supplementary Fig. 2 in the Supplementary Materials demonstrates the effects of the parameters $\lambda_h$ and $\lambda_r$.

**The complete model**

The complete model is then,

$$
\frac{d}{dt}X(t, \tau) = \lambda(t, \tau) - d(X, t, \tau)X(t, \tau) + p(X, t, \tau)X(t, \tau),
$$

where
\[ \lambda(t, \tau) = \lambda_0 \lambda_{age} \Delta_{HSC}(t) \]  
\[ p(X, t, \tau) = y(\tau)p_0 e^{c_p \left(1 \frac{X(t)}{N(\tau)}\right)} \]  
\[ d(X, t, \tau) = y(\tau)d_0 e^{c_d \left(\frac{X(t)}{N(\tau)} - 1\right)} \]  

with \( X(0, \tau) \) the estimated parameter \( X_0 \).

**Model fitting**

Identifiability analysis using the FME package \(^4^1\) in R 2.15.1 \(^4^2\), demonstrated that the effects of the parameters for the strength of competition for resources, \( c_p \) and \( c_d \), on the curve of the reconstitution could be absorbed into other parameters. As such they were fixed to 1. All other parameters were estimated with both fixed and random effects, with a full variance-covariance matrix estimated for the random effects. All model parameters were lognormally distributed and the additive residual error model was applied to log-transformed CD4 counts.

Non-linear mixed effects (NLME) modelling with NONMEM 7.3 \(^4^3\) was used. The Importance Sampling expectation-maximisation algorithm \(^4^4\) algorithm was used. Quality of fit was assessed using diagnostic plots (Fig. 4). Conditional weighted residuals were approximately normally distributed with mean 0 and variance 1 and independent of time and population prediction. Model misspecification was assessed with a visual predictive check (VPC), whereby for each datapoint in the observed data, 600 data points were simulated from the model using the parameter estimates and variance-covariance matrix. Having ascertained that the model fit the observed data, this ascertained that model-simulated data matched the observed data albeit with some deviations at later time points. The VPC was produced using PsN 3.5.3 \(^4^5\).
Covariate model-building

A total of 34 covariates were chosen which could potentially influence CD4 reconstitution. These fell into the following categories: diagnosis, pre-transplant conditioning, stem cell source, post-transplant immunosuppressant regimen, and post-transplant outcomes (e.g. GvHD, graft failure, presence of viral infection). All covariates were dichotomous and entered the model as follows: \( \text{typical parameter value} \times (1 + \theta_{\text{cov}}) \), where \( \theta_{\text{cov}} \) was the proportional change in typical parameter value in the presence of the covariate. Further details are given in Supplementary materials. These were included using stepwise covariate model-building (SCM) \(^4^6\) whereby during the forward search covariates were tested on each parameter, with the one yielding best fit retained for the next step until no more covariates lead to significant improvement in fit. During backwards elimination covariates from the forward search are excluded in a step-wise manner with stricter significance criteria. Since models are nested, a likelihood ratio test at each step with the difference in \(-2\ln(\text{likelihood})\) asymptotically \( \chi^2_n \) distributed (where \( n \) is the difference in the number of nested parameters).

In the forward search we used an inclusion criteria of \( p<0.01 \) and in the backwards elimination \( p<0.005 \), and SCM was implemented using PsN 3.5.3 \(^4^5\).

Predicting reconstitution from early data and individual covariates

The population parameter means and variances found from the initial model fitting were used as the priors. The posterior individual-level parameter values using data from the first 6 months post transplant were then found through expectation-only importance sampling steps using the covariate model and parameter estimates from the model-building dataset. In this process, the conditional (posterior) mean and variance of individual parameters were evaluated by Monte Carlo sampling, and the likelihood of these individual parameters was maximised given the fixed population means and variances and the individual’s observed data \(^4^4\).
Predicted trajectories were then formed from these individual parameters: 500 sample parameter sets were simulated from the parameter means and their variance-covariance matrix. From these sample curves, the median and confidence intervals were found for the trajectory of that individual’s CD4 T cell reconstitution.

**Code availability**

An R script is included in the Supplementary Materials that produces predictions for an individual child. It formats data, runs the NONMEM script with the model also in the Supplementary Materials and finally produces a graphical output of the prediction for that patient.
6 Study Highlights

• What is the current knowledge on the topic?

The rate and extent of CD4 T cell recovery post stem cell transplant has been studied separately in selected groups of patients through summarising counts at certain time points or the time to reach a certain count.

• What question did this study address?

Using a mechanistic nonlinear mixed effects model, can we simultaneously model rate and extent using data from all available patients with heterogenous diagnoses, stem cell sources and therapeutic conditioning protocols? What are the key patient factors associated with CD4 T cell recovery?

• What this study adds to our knowledge?

A single mechanistic model can be used to fit heterogeneous data on CD4 T cell recovery in children. The important factors associated with CD4 T cell reconstitution have been identified and quantified with time.

• How this might change clinical pharmacology or translational science

There are two major uses of the model: Firstly in predicting CD4 T cell recovery it can be used to inform future study and/or clinical protocol design of novel conditioning protocols; secondly, as a Bayesian tool to predict CD4 T cell recovery in individual patients to inform clinical practice.
7 Author Contributions

RH, RC, and JS designed the research, RH developed the model with clinical input from PV and NK, immunological input from RC and statistical modelling input from JS. RH wrote the manuscript with input from all authors.

8 Acknowledgements

RH was supported by an Engineering and Physical Sciences Research Council Life Sciences Interface Doctoral Training Centre studentship at the Centre for Mathematics and Physics in the Life Sciences and Experimental Biology (CoMPLEX). JS was supported by a United Kingdom Medical Research Council Fellowship (grant G1002305). The authors would like to thank Prof Rodolphe Thiebaut of the University of Bordeaux for comments on the manuscript.

9 Financial disclosure

No authors have any financial relationships to disclose which may concern this manuscript.
References


List of Figures

Figure 1: Data for CD4 T-cell reconstitution following pediatric HSCT (n=319). This is the data that was used in the model development and covariate analysis. Each coloured line is the data for an individual transplant. The thick black line gives a local regression (LOESS) curve for the data.

Figure 2: Schematic of the model. The compartment \( X(t) \) represents CD4 T cell concentration in the peripheral blood with time \( t \) after HSCT. New cells output by the thymus enter the compartment at zero-order rate \( \lambda \) and cells proliferate into two cells or die at first-order rates \( p \) and \( d \) respectively. Scaling for age was added to \( \lambda \), \( p \) and \( d \) and a function causing a time delay in the recovery of \( \lambda \) after transplant was also used.

Figure 3: The effects of the significant covariates (\( P<0.005 \), based on a likelihood ratio test) on the CD4 reconstitution of patients of 6 months, 12 months, 37 months (median age) and 5 years old at the time of HSCT. A typical individual is one that is not in each of the covariate groups listed. The expected curve of a healthy child uses the function for \( N(t) \) given in the Methods section 2. Each other trajectory gives the effects of the significant covariates, included through the SCM procedure. Conditioning drugs alemtuzumab (n=158) and ATG (n=10) and acute GvHD (n=102) affect initial number of cells, while leukaemia (n=95) and having no conditioning (n=41) affect long-term reconstitution.

Figure 4: Diagnostic plots for the model. a and b give population and individual predictions versus observations; c and d give conditional weighted residuals (CWRES) against time and population prediction respectively; e gives a visual predictive check (VPC): dots give the observed data, the solid black line the observed median, and the dashed black lines the observed 95% prediction intervals. The grey shaded areas gives the 95% confidence intervals for the predicted median and for the predicted 95% prediction intervals.

Figure 5: Examples of predicted reconstitution (9 patients out of the 75 that were modelled) where the model achieved a good prediction, listed in age order. The circles are the data points that were used to make the predictions, and the crosses are the data not used in forming predictions, for comparison to the predictions. The line is the median prediction, with the green shaded area giving the 90% confidence intervals. The blue line and shaded area are the median and 90% confidence intervals of the expected CD4 concentration of a healthy child of this age.
List of Tables

Table 1: Typical model parameter estimates with standard deviations, and random effect variances with standard deviations.

Table 2: Percentage breakdown of the demographics and the drugs used for the patients in the datasets, all of which were tested as covariates. M: Model-building dataset (n=319), used for model building and covariate analysis; V: Validation dataset (n=75), used for assessing the predictive ability of the model.
CD4 T cell Concentration $X(t)$

This article is protected by copyright. All rights reserved.
CD4 concentration (cells/µL)

Time after HSCT (months)

- Expected for a healthy child
- Typical individual
- Alemtuzumab
- Antithymocyte globulin
- Acute GvHD
- Leukaemia
- No conditioning

This article is protected by copyright. All rights reserved.
Table 1: Typical model parameter estimates with standard deviations, and random effect variances with standard deviations.

<table>
<thead>
<tr>
<th>Structural Model</th>
<th>Estimate</th>
<th>s.d.</th>
<th>Ω</th>
<th>s.d.</th>
</tr>
</thead>
<tbody>
<tr>
<td>$\lambda_{do4}(0)$</td>
<td>Proportion of theoretical thymic output $^{13}$ (cells/day)</td>
<td>0.216</td>
<td>0.0711</td>
<td>1.57</td>
</tr>
<tr>
<td>$d_{0}$</td>
<td>Proportion of expected loss (/day)</td>
<td>0.477</td>
<td>0.0959</td>
<td>1.62</td>
</tr>
<tr>
<td>$p_{0}$</td>
<td>Proportion of expected proliferation (/day)</td>
<td>0.207</td>
<td>0.0239</td>
<td>0.251</td>
</tr>
<tr>
<td>$X_{0}$</td>
<td>Initial concentration of T cells (cells/μL)</td>
<td>168</td>
<td>21.5</td>
<td>1.31</td>
</tr>
<tr>
<td>$\lambda_{do4}(h)$</td>
<td>Time to recovery in thymic output (days)</td>
<td>133</td>
<td>20.3</td>
<td>1.27</td>
</tr>
<tr>
<td>$\lambda_{do4}(r)$</td>
<td>Rate of recovery in thymic output</td>
<td>9.66</td>
<td>1.36</td>
<td>1.22</td>
</tr>
<tr>
<td>$\sigma$</td>
<td>Variance of the residual error</td>
<td>0.219</td>
<td>0.0167</td>
<td>—</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Covariate Model</th>
<th>Covariate</th>
<th>Effect size</th>
<th>s.d.</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>$X_{0}$</td>
<td>Alemtuzumab</td>
<td>-0.842</td>
<td>0.029</td>
<td>≪0.001</td>
</tr>
<tr>
<td>$X_{0}$</td>
<td>Antithymocyte globulin</td>
<td>-0.939</td>
<td>0.052</td>
<td>≪0.001</td>
</tr>
<tr>
<td>$X_{0}$</td>
<td>Acute GvHD</td>
<td>0.283</td>
<td>0.196</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>$X_{0}$</td>
<td>Leukaemia</td>
<td>1.32</td>
<td>0.442</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>$X_{0}$</td>
<td>No conditioning</td>
<td>-0.844</td>
<td>0.025</td>
<td>≪0.001</td>
</tr>
</tbody>
</table>

Parameter estimates and the random effect variances (Ωs) were estimated from the model-building dataset. The standard deviations (s.d.) for both the parameter means and for the variances of the random effects were found through 200 bootstrap samples using PsN 3.5.3. The significant categorical covariates were included through multiplication of the parameter by (1 + Effect size), testing the null hypothesis that the effect size is zero.
Table 2: Percentage breakdown of the demographics and the drugs used for the patients in the datasets, all of which were tested as covariates. M: Model-building dataset (n=319), used for model building and covariate analysis; V: Validation dataset (n=75), used for assessing the predictive ability of the model.

<table>
<thead>
<tr>
<th>Age at HSCT (years)</th>
<th>Diagnosis</th>
<th>HSCT</th>
</tr>
</thead>
<tbody>
<tr>
<td>0–1</td>
<td>Immunodeficiencies 4340</td>
<td>1st 8588</td>
</tr>
<tr>
<td>1–2</td>
<td>SCID 2624</td>
<td>2nd 1311</td>
</tr>
<tr>
<td>2–5</td>
<td>Wiskott-Aldrich 4 7</td>
<td>3rd 1 1</td>
</tr>
<tr>
<td>5–10</td>
<td>CGD 4 8</td>
<td>GvHD</td>
</tr>
<tr>
<td>10+</td>
<td>Leukaemia 3023</td>
<td>Reported 32 60</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Sex</th>
<th>M</th>
<th>V</th>
</tr>
</thead>
<tbody>
<tr>
<td>Male</td>
<td>1411</td>
<td>1233</td>
</tr>
<tr>
<td>Female</td>
<td>6368</td>
<td>1118</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Stem cells</th>
<th>M</th>
<th>V</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bone/marrow</td>
<td>4736</td>
<td>1527</td>
</tr>
<tr>
<td>Peripheral blood</td>
<td>3837</td>
<td>3864</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Donor type</th>
<th>M</th>
<th>V</th>
</tr>
</thead>
<tbody>
<tr>
<td>Matched</td>
<td>6352</td>
<td>186</td>
</tr>
<tr>
<td>Sibling</td>
<td>2719</td>
<td>78</td>
</tr>
<tr>
<td>Family</td>
<td>5 7</td>
<td>3 7</td>
</tr>
<tr>
<td>Unrelated</td>
<td>3127</td>
<td>3127</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Prophylaxis</th>
<th>M</th>
<th>V</th>
</tr>
</thead>
<tbody>
<tr>
<td>Adenovirus</td>
<td>2936</td>
<td>33 3</td>
</tr>
<tr>
<td>Autologous</td>
<td>1 8</td>
<td>67 7</td>
</tr>
</tbody>
</table>

| Abbreviations: SCID: severe combined immunodeficiency syndrome; CGD: chronic granulomatous disease; ALL: acute lymphoblastic leukaemia; AML: acute myeloid leukaemia; HLH: hemophagocytic lymphohistiocytosis; GvHD: graft versus host disease. Positive for CMV, EBV or adenovirus was defined as detectable virus post-transplant. |